skip to navigation skip to content
Search

pharmaceuticals

Drug trials: what value should pharma firms assign to rivals’ success?

Drug companies pay close attention to early-stage investment and testing by rivals, but only successful demonstrations of clinical proof of concept really matter, says new study co-authored at Cambridge Judge Business School. As in all competitive industries, pharmaceutical companies carefully…

Read more

Drug development is uncertain and complex, and firms need to be cautious when reading into decisions taken by rivals.

Venturing forth: Qureight – integrating data with AI to solve complex diseases

Qureight, a clinical data analytics company supported by the Accelerate Cambridge programme at Cambridge Judge Business School, just raised £1.5m in seed funding. Qureight, a clinical data analytics firm supported by Cambridge Judge Business School, had its origins in a…

Read more

Venturing forth: Qureight – integrating data with AI to solve complex diseases.

India Education Diary: New book highlights how small biotech companies are outperforming big pharma

From Breakthrough to Blockbuster: The Business of Biotechnology, a new book co-authored by Nektarios Oraiopoulos, Associate Professor at Cambridge Judge Business School, shows how small, inexperienced entrepreneurial companies making up the biotech industry have created more life-changing medicines than all…

Read more

Carryover co-operation

Sir Mene Pangalos of AstraZeneca, in a Cambridge Judge interview, urges continuation of the 'exceptional' collaboration between industry, academia, government and regulators that led to rapid development of COVID-19 vaccines. Sir Mene Pangalos The "exceptional" collaboration between the pharmaceutical industry,…

Read more

Female scientist looking at ampoule with new medication, vaccination development.

Biopharm expansion

Apollo Therapeutics, a life sciences company led by Cambridge Judge Business School alumnus and Fellow Dr Richard Mason, completes $145 million financing. Apollo Therapeutics, a biopharmaceutical company headed by Cambridge Judge Business School MBA alumnus and Fellow Dr Richard Mason…

Read more

Scientists working in a modern laboratory.

United Press International: Study: Second opinion can reduce risk for long-term opioid use

A study looking at opioid use co-authored by Stefan Scholtes, Dennis Gillings Professor of Health Management at Cambridge Judge Business School, featured in United Press International. The study found that “a “second opinion” by another prescribing doctor within 30 days…

Read more

Opioid intervention

'Second opinion' by another prescribing doctor within 30 days of an opioid prescription reduces long-term opioid use by 31%, concludes a new study led at Cambridge Judge Business School. A "second opinion" by another prescribing doctor within 30 days of…

Read more

High angle view of a prescription bottled filled with pills surrounded by more of the same tablets, with copy space,

Stock sales

Three US senators cite research by Professor Alan Jagolinzer of Cambridge Judge Business School in urging SEC reform of insider trading laws.  Professor Alan Jagolinzer Three US senators cited research co-authored by Professor Alan Jagolinzer of Cambridge Judge Business School in urging the Securities…

Read more

Woman tracking and trading stocks using laptop and desktop computer. Stock Exchange, investment, and financial trading concept.

Good reporting

Annual reports should inform society – not just shareholders – about vital issues such as the financial health and environmental impact of organisations, says Professor Alan Jagolinzer of Cambridge Judge Business School. Professor Alan Jagolinzer By Professor Alan Jagolinzer Corporate…

Read more

Business people discussing an annual report.

Forbes India: How drug companies can increase their R&D effectiveness

A study co-authored by Professor Stylianos Kavadias and Dr Nektarios Oraiopoulos at University of Cambridge Judge Business School, is featured in the Forbes article. The study demonstrates “how pharmaceutical executives can impact the success of their research and development” programs…

Read more

Archives